News | October 26, 2021
ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated
